LD-2 disclosure · 1st Quarter - Report
MT PHARMA AMERICA, INC.
Client
- Name
- MT PHARMA AMERICA, INC.
- Description
- Pharmaceutical Company
- Location
- New Jersey · United States of America
Registrant
- Description
- Lobbying Law Firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesBudget/Appropriations
Budget reconciliation and the American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).
LobbyistsGEORGE OLSEN
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
Matters affecting access to and pricing of pharmaceuticals; matters affecting the Orphan Drug Act and therapies for rare diseases; legislation and regulatory activity relating to importation of prescription drugs; drug pricing including Medicare rebate reform, the 340B drug discount program, Buy America requirements, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. Legislation to improve access to treatments for ALS. The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).
LobbyistsGEORGE OLSEN · mr DAVID A STARR · CHERYL LYNN JAEGER
Covered position (CHERYL LYNN JAEGER): Shd employee, Ofc of the Speaker 7 Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Matters affecting access to and payment for pharmaceuticals under Medicare; Medicare coverage and payment for home infusion of drugs during the COVID-19 pandemic public health emergency. Matters concerning Medicare prescription drug rebate reform, the 340B drug discount program, Buy America requirements, drug importation, and imposition of most favored nation pricing on drugs under Medicare Parts B and D. The American Rescue Plan Act of 2021 (H.R. 1319, now Public Law No. 117-2).